老年医学

订阅

MedSci主页 / 所有栏目 / 老年医学

2019年美国眼科学会：基因疗法ADVM-022治疗湿性AMD的24周数据

2019-08-29 Allan MedSci原创

ADVM-022基因疗法湿性AMD
关注

Adverum是一家针对眼部疾病的临床阶段基因治疗公司，近日宣布，玻璃体内注射基因疗法ADVM-022治疗湿性AMD的临床试验已经取得阶段性成果，第一批患者（n=6）的24周数据将于2019年10月11日在加利福尼亚州旧金山举行的美国眼科学会（AAO）年会上公布。

Adverum是一家针对眼部疾病的临床阶段基因治疗公司，近日宣布，玻璃体内注射基因疗法ADVM-022治疗湿性AMD的临床试验已经取得阶段性成果，第一批患者（n=6）的24周数据将于2019年10月11日在加利福尼亚州旧金山举行的美国眼科学会（AAO）年会上公布。

Adverum Biotechnologies首席医疗官，Aaron Osborne说：“湿性AMD是一种侵袭性疾病，通常需要长期进行抗VEGF治疗以减少视力丧失。ADVM-022使用单一的标准疗法进行治疗，我们相信这有可能显著降低治疗负担并改善湿性AMD患者的实际视力结果”。


原始出处：

http://www.firstwordpharma.com/node/1662538?tsid=4#axzz5xwhWnSXE

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019198, encodeId=31cf201919822, content=<a href='/topic/show?id=ef95e286296' target=_blank style='color:#2F92EE;'>#眼科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72862, encryptionId=ef95e286296, topicName=眼科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat May 02 02:12:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316007, encodeId=502c131600e81, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Aug 31 02:12:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371962, encodeId=2ade3e19629d, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Aug 29 12:27:56 CST 2019, time=2019-08-29, status=1, ipAttribution=)]
    2020-05-02 lilili1104

    #眼科学#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2019198, encodeId=31cf201919822, content=<a href='/topic/show?id=ef95e286296' target=_blank style='color:#2F92EE;'>#眼科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72862, encryptionId=ef95e286296, topicName=眼科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat May 02 02:12:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316007, encodeId=502c131600e81, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Aug 31 02:12:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371962, encodeId=2ade3e19629d, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Aug 29 12:27:56 CST 2019, time=2019-08-29, status=1, ipAttribution=)]
    2019-08-31 zhty5337

    #AMD#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2019198, encodeId=31cf201919822, content=<a href='/topic/show?id=ef95e286296' target=_blank style='color:#2F92EE;'>#眼科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72862, encryptionId=ef95e286296, topicName=眼科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat May 02 02:12:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316007, encodeId=502c131600e81, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Aug 31 02:12:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371962, encodeId=2ade3e19629d, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Aug 29 12:27:56 CST 2019, time=2019-08-29, status=1, ipAttribution=)]
    2019-08-29 1ddf0692m34(暂无匿称)

    学习了，谢谢分享

    0